Immunotherapy is now a first-line treatment in the overall management of lung cancer, but the inclusion of immunotherapy and whether it is based on PD-L1 expression in the subgroup of SMARCA4-UT remains inconclusive. Here, SMARCA4 is linked to lung cancer.